Gamma Delta T Therapies continue to spark interest whereby their unique biological features are being targeted to better tackle solid tumors. In 2024, the community is poised at a pivotal juncture, intensifying efforts to comprehensively grasp the clinical safety and efficacy of gamma delta T therapies. This summit aims to solidify confidence in the transformative potential of this approach within the realms of cell therapy and antibody development. 

This year the 5th Gamma Delta T Therapies Summit has brought together experts from big pharma, biotech and academia to delve into the details of gamma delta biology and its various subsets to offer the audience a well-rounded overview of the landscape currently and the steps needed for it to move forward. 

With a world-class speaker faculty sharing the latest insights in the field, this meeting continues to be the one-stop shop to accelerate your gamma delta T therapies by determining best CMC manufacturing practices, novel engineering strategies for vd1/vd2 subsets, how to design a robust clinical design strategy and lessons learned from phase 1 and 2 clinical trials.  

Take this opportunity to upskill your cross-functional team across discovery, translation, clinical development, CMC and manufacturing to successfully translate basic research into your clinical strategy to support your IND submission.